Description：ELISA for the detection of bispecific antibody Gresonitamab in human serum and plasma.
Lead time for this kit is 5 weeks.
About the kit： - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％ - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life： 1 year.Gresonitamab is an IgG-1 T cell engaging bispecific antibody directed against the tumor-associated antigen （TAA） claudin.
It simultaneously binds CLDN18 and CD3e, and is currently being investigated for its therapeutic effects on gastroesophageal junction adenocarcinoma.
仕様
サイズ：1 x 96 wells
Reactivity：Human
アプリケーション：ELISA,Immunoassay
Sensitivity：Please refer to the current IFU for the updated calibrator range and sensitivity.
